“The prostate cancer risk calculator has been updated using current risk factors and a better interface; the current version gives a more nuanced result that helps understand a man’s risk of prostate cancer,” said Ian M. …
“The prostate cancer risk calculator has been updated using current risk factors and a better interface; the current version gives a more nuanced result that helps understand a man’s risk of prostate cancer,” said Ian M. Thompson Jr., M.D., director of the Cancer Therapy & Research Center at the UT Health Science Center, who helped develop the risk calculator and co-authored a commentary published today in the Journal of the American Medical Association. The free calculator on the Health Science Center website takes just minutes to use and gives a man more information about his risk for both low-grade prostate cancer, which may never require treatment, and high-grade prostate cancer. It provides an “emoji” graphic readout that puts the numeric percentages into a visual perspective. …
In a paper published in the journal Proceedings of the National Academy of Sciences, Sangeeta Bhatia of MIT and Charles Rice of Rockefeller University describe using microfabricated cell cultures to sustain hepatitis B virus in human liver cells, allowing them to study immune responses and drug treatments. …
Despite there currently being a wide variety of compounds against cancer, they all have serious side effects. Furthermore, tumours are capable of becoming resistant, limiting this type of treatment. …
The value of mammography screening in older women has been subject to much debate in recent years. The American Cancer Society recommends annual mammograms for women age 75 and older as long as they are in good health, while the U.S. Preventive Services Task Force (USPSTF) does not recommend mammography screening in this age group, citing insufficient evidence to evaluate benefits and harms. A lack of research is chiefly responsible for the divergent recommendations, according to Judith A…
The effort is known as the Institutional Multidisciplinary Paradigm to Accelerate Collaboration and Translation (IMPACT). The aim — as illustrated in the acronym — is to enhance the way cancer discoveries are translated from the laboratory bench to patient bedside and back again. …
“We have found a promising technique for type 1 diabetics to restore the body’s ability to produce insulin. By introducing caerulein to the pancreas we were able to generate new beta cells — the cells that produce insulin — potentially freeing patients from daily doses of insulin to manage their blood-sugar levels.” said Fred Levine, M.D., Ph.D., professor and director of the Sanford Children’s Health Research Center at Sanford-Burnham. The study first examined how mice in which almost all beta cells were destroyed — similar to humans with type 1 diabetes — responded to injections of caerulein. …
The markers are variations in the inherited DNA code at particular locations along chromosomes. Several of these variations in the DNA code were identified that influence an individual’s risk for pancreatic cancer. The discovery of these markers — along with four that were previously identified is important for several reasons, said Brian Wolpin, MD, MPH, first author of the report published online by Nature Genetics…
“Research in breast cancer has lately allowed to characterize molecular features that have increasingly become the targets for novel therapeutic interventions. …
“It is well-established that individual tumors are genetically heterogeneous — comprised of multiple subgroups of cancer cells, each with its own genomic signature, or pattern of gene mutations,” said the study’s senior author, Kornelia Polyak, MD, PhD, of Dana-Farber. …